


IRAK4-IN-14

Cat. No.:	HY-146112
CAS No.:	2667681-71-0
Molecular Formula:	C ₂₅ H ₂₈ FN ₉ O
Molecular Weight:	489.55
Target:	IRAK
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	IRAK4-IN-14 (compound 28) is a potent, selective and orally active IRAK4 inhibitor with an IC ₅₀ of 0.003 μM. IRAK4-IN-14 shows good PK parameters in rats and mouse. IRAK4-IN-14 shows synergistic in vitro activity against MyD88/CD79 double mutant ABC-DLBCL in combination with Acalabrutinib ^[1] .																
IC₅₀ & Target	IRAK4 0.003 μM (IC ₅₀)																
In Vitro	IRAK4-IN-14 (compound 28) shows cell pIRAK4 potencies with an IC ₅₀ of 0.11 μM ^[1] . IRAK4-IN-14 (compound 28) shows selectivity with IC ₅₀ s of 0.003, 1.4, >8, >9, 0.053, 0.27, 0.76, 0.27 μM for IRAK4, IRAK1, BTK, FIt3, PI3Kδ, TRKa, TRKb, TRKc, respectively ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.																
In Vivo	IRAK4-IN-14 (i.v. or p.o.) shows good PK parameters with oral bioavailability of 66% for mouse ^[1] . Pharmacokinetic Parameters of IRAK4-IN-14 in Male Han Wistar rats, male CD1 mice, male Cynomolgus monkeys ^[1] . <table border="1" data-bbox="345 1339 1372 1953"> <thead> <tr> <th>parameter</th> <th>Value</th> </tr> </thead> <tbody> <tr> <td>A2B P_{app}</td> <td>31</td> </tr> <tr> <td>Efflux ratio</td> <td>1.4</td> </tr> <tr> <td>Solubility (μM)</td> <td>800</td> </tr> <tr> <td>Rat/mouse/monkey/human %free</td> <td>21/16/33/21</td> </tr> <tr> <td>Rat LM/H CL_{int}</td> <td>16/5.6</td> </tr> <tr> <td>Mouse LM/H CL_{int}</td> <td>13/11</td> </tr> <tr> <td>Minipig LM/H CL_{int}</td> <td>18/8.2</td> </tr> </tbody> </table>	parameter	Value	A2B P _{app}	31	Efflux ratio	1.4	Solubility (μM)	800	Rat/mouse/monkey/human %free	21/16/33/21	Rat LM/H CL _{int}	16/5.6	Mouse LM/H CL _{int}	13/11	Minipig LM/H CL _{int}	18/8.2
parameter	Value																
A2B P _{app}	31																
Efflux ratio	1.4																
Solubility (μM)	800																
Rat/mouse/monkey/human %free	21/16/33/21																
Rat LM/H CL _{int}	16/5.6																
Mouse LM/H CL _{int}	13/11																
Minipig LM/H CL _{int}	18/8.2																

Dog LM/H CL _{int}		21/4.5
Monkey LM/H CL _{int}		35/4.7
Rat	CL	15
	Vd _{ss}	4.3
	t _{1/2}	5.2
	F%	55%
Mouse	CL	17
	Vd _{ss}	4.1
	t _{1/2}	4.2
	F%	66%
Monkey	CL	68
	Vd _{ss}	8.6
	t _{1/2}	1.4

Male Han Wistar rats; 1 mg/kg i.v.; 2 mg/kg p.o.; Male CD1 mice; 0.5 mg/kg i.v.; 1 mg/kg p.o.; Male Cynomolgus monkeys; 1 mg/kg i.v.^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Degorce SL, et al. Improving metabolic stability and removing aldehyde oxidase liability in a 5-azaquinazoline series of IRAK4 inhibitors. *Bioorg Med Chem*. 2020 Dec 1;28(23):115815.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA